First Results From Editas CRISPR Eye Therapy Underwhelm Investors
Safety Is Reassuring But Efficacy Unclear
While rivals Intellia impressed with their first in vivo CRISPR gene-editing data, Editas’s first results in just two patients are not enough to convince investors.
